SCHEMBL1301384

SCHEMBL1301384

COc1nc2c(cc1NCc1c(F)ccc(F)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 1/20 0.43
▸ GSK3B P49841 2/20 0.33
▸ JAK2 O60674 5/20 0.33
▸ JAK3 P52333 5/20 0.33
▸ JAK1 P23458 4/20 0.33
▸ CD38 P28907 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ ATP6V1B2 P21281 1/20 0.31
▸ TBXA2R P21731 1/20 0.31
▸ EDNRA P25101 1/20 0.31
▸ TARBP2 Q15633 1/20 0.31
▸ RIPK1 Q13546 2/20 0.31
▸ TYK2 P29597 1/20 0.30
▸ PIM1 P11309 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ P2RX7 Q99572 2/20 0.30
▸ CHRM1 P11229 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1301388 1.00 METTL3 (0.43) METTL3GSK3BJAK2JAK3JAK1
SCHEMBL1300924 0.93 METTL3 (0.46) METTL3GSK3BJAK2JAK3JAK1
SCHEMBL1300920 0.93 METTL3 (0.46) METTL3GSK3BJAK2JAK3JAK1
SCHEMBL1301826 0.91 METTL3 (0.45) METTL3GSK3BLMNACYP2C9ATP6V1B2
SCHEMBL1301823 0.91 METTL3 (0.45) METTL3GSK3BLMNACYP2C9ATP6V1B2
SCHEMBL1300334 0.90 METTL3 (0.41) METTL3GSK3BJAK2JAK3LMNA
SCHEMBL1300337 0.90 METTL3 (0.41) METTL3GSK3BJAK2JAK3LMNA
SCHEMBL1301707 0.89 METTL3 (0.49) METTL3GSK3BCD38KDM4EP2RX7
SCHEMBL1301713 0.89 METTL3 (0.49) METTL3GSK3BCD38KDM4EP2RX7
SCHEMBL1300860 0.89 METTL3 (0.42) METTL3GSK3BKDM4EP2RX7CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885GSK3B 524/4885JAK2 4141/4885
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885GSK3B 524/4885JAK2 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback